Italia markets closed

bioMérieux S.A. (BIM.PA)

Paris - Paris Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
100,70-0,70 (-0,69%)
Alla chiusura: 05:35PM CEST

bioMérieux S.A.

376 Chemin De l’Orme
Marcy l'Étoile 69280
France
33 4 78 87 20 00
https://www.biomerieux.com

Settore/iHealthcare
SettoreDiagnostics & Research
Impiegati a tempo pieno13.409

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Pierre BouludChief Executive Officer1,35MN/D1971
Mr. Guillaume BouhoursExecutive VP of Purchasing and Information Systems & CFON/DN/D1976
Sylvain MorgeauInvestor RelationsN/DN/DN/D
Ms. Audrey DauvetExecutive Vice President of Legal, Corporate Integrity & Public AffairsN/DN/D1974
Ms. Valerie LeyldeExecutive Vice President of Human Resources, Communications & CSRN/DN/DN/D
Mr. Pierre CharbonnierExecutive Vice President of Global Quality, Manufacturing & Supply ChainN/DN/DN/D
Mr. Yasha MitrottiExecutive Vice President of Industrial ApplicationsN/DN/DN/D
Mr. Frederic BesemeHead of CSR21,99kN/D1956
Jennifer ZinnExecutive Vice President of Clinical OperationsN/DN/DN/D
Charles K. CooperExecutive VP & Chief Medical OfficerN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Governance aziendale

L'ISS Governance QualityScore di bioMérieux S.A. al 1 aprile 2024 è 9. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 8; diritti degli azionisti: 8; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.